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Introduction
Extracorporeal shock wave lithotripsy (SWL) has revolution-
ized treatment for most patients with urolithiasis since its
introduction in the early 1980s.1,2 However, uric acid stones
were once regarded as a relative contraindication for SWL
with the Dornier HM3 lithotripter because of the difficulty
in localizing the radiolucent stones with fluoroscopy.3,4
Today, the second generation of lithotripters with ultrasound
guidance allow more accurate and harmless localization of
radiolucent stones. There have been few reports of treating
uric acid stones, which are radiolucent or lightly radio-
opaque, with SWL. We herein report our series of patients
with uric acid stones in the kidney or ureter. These cases
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were treated with SWL using different ultrasound-guided
lithotripters in combination with urine alkalization.
Patients and methods
From December 1987 to December 2003, we treated 443
patients with uric acid stones in the kidney or ureter. A total
of 168 patients underwent SWL with an EDAP LT-01
lithotripter and 275 patients underwent SWL with a Dornier
Compact S lithotripter (Table 1). All patients suffered re-
current pain, gross haematuria and/or urinary obstruction
before SWL. The average stone size was calculated from
ultrasound as follows: average stone size (mm) = 1/2 (length +
width).
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Stones smaller than 5 mm, which can be dissolved by alkali
therapy before SWL, were excluded from the series.
All patients were evaluated preoperatively using physical
and laboratory examinations. Patients with radiolucent stones
underwent metabolic evaluation including detailed serum
and 24-hour urine biochemical tests. Intravenous urography
and ultrasonography were performed before SWL. Retrograde
pyelography was used when necessary.
Patients with sterile urine were given oral norfloxacin
preoperatively, while those with known bacteriuria were
treated with culture-specific antibiotics before SWL. Patients
treated with the EDAP LT-01 lithotripter were given 5 mg
valium orally 1 hour before SWL and those treated with the
Dornier Compact S were given an intramuscular injection
of 50 mg petidine at the beginning of lithotripsy after stone
localization.
Postoperative ultrasonography was obtained 3 days after
SWL for comparison with preoperative ultrasonography; com-
puted tomography was used if necessary. The degree of frag-
mentation was assessed. Stone-free was defined as a complete
absence of any fragments in the upper urinary tract after
treatment. All the passed stone fragments were collected and
analysed using infrared spectroscopy and polarizing micros-
copy. These fragments were pure or predominantly uric acid.
After SWL, all patients were advised to drink copious amounts
of water and take a supplement of sodium bicarbonate (3 g/
day) or potassium citrate (9 g/day) for 2–3 weeks to maintain
a urine pH of 6.5–7.0. Patients with preoperative bacteriuria
were treated after SWL for 10 days with culture-specific anti-
biotics and re-examined. If patients were not stone-free 3 days
after SWL, follow-up would continue for 3 weeks to 3 months.
Results
In the 168 patients treated with the EDAP LT-01 lithotripter,
treatment time for renal stones ranged from 20 to 70 minutes
(mean, 48.9 minutes), and for ureteral stones ranged from 48
to 70 minutes (mean, 60.4 minutes). The power was 100%
and the pulse frequency was 1.25–2.5 shocks per second. The
overall mean SWL treatment time for renal and ureteral stones
was 52.1 minutes.
In the 275 patients treated with the Dornier Compact S
lithotripter, treatment was started at low voltage, which was
then gradually increased. For renal stones, 1,900–3,500 shocks
(mean, 2,960) were used at a voltage ranging from 10 to 15 kV
(mean, 14.8 kV). For ureteral stones, 3,000–4,000 shocks (mean,
3,294) were used at a voltage ranging from 10 to 16 kV (mean,
14.9). The mean treatment parameters of the Dornier Com-
pact S lithotripter for renal and ureteral stones were 3,196
shocks at 14.8 kV.
Table 2 summarizes the results for all stones. For both
lithotripters, the overall stone-free rates at 3 weeks and 3
months after SWL were 66.3% and 88.5%, respectively. The
stone-free rates and retreatment rates were related to the size
and location of the stones; results were better for stones
smaller than 20 mm, and retreatment rates for larger stones
were higher than those for smaller stones. No anaesthesia was
required for in situ SWL with either lithotripter. In two cases,
difficulties in detecting upper ureteral stones located at the L4
level with ultrasound-guided lithotripters limited in situ SWL,
so a ureteral catheter was inserted under spinal block. The
Table 1. Patient demographics
Lithotripter n Age (range), yr Male:female ratio Stone size (range), mm
EDAP LT-01 168 40 (20–78) 2.9:1 9.1 (5–35)
Dornier Compact S 275 45 (23–66) 3.8:1 9.6 (7–28)
Table 2. Stone location and clinical results of shock wave
lithotripsy
Criteria
EDAP LT-01 Dornier Compact S
(n = 168) (n = 275)
Stone location, %
Kidney 83.9 89.1
Ureter
Upper 10.7 05.8
Middle 00.7
Lower 05.4 04.4
Treatment data, %
Auxiliary procedure 08.9 13.0
Retreatment 24.2 29.0
Stone-free
3 wk 63.6 70.1
3 mo 86.4 90.3
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ureteral stones were pushed back and treated successfully in
the pelvis.
During SWL, complications were mild (Table 3). Only 3%
of patients suffered vagal reactions with nausea, vomiting,
sweating, bradycardia and hypotension during piezoelectric
SWL. If necessary, the procedure was stopped for a moment
and patients were given an intramuscular injection of 0.5 mg
atropine, then SWL was resumed without problem. After SWL,
one patient suffered from urinary tract infection with body
temperature higher than 39$C and was treated using intrave-
nous fluids and antibiotics. No significant perinephric hae-
matoma was noted in any case during follow-up. Table 4
shows the results of stone composition analysis by infrared
spectroscopy and polarized microscopy.
Discussion
SWL is generally accepted as a standard method for the treat-
ment of renal or ureteral stones. According to our results, the
treatment of uric acid stones with ultrasound-guided
lithotripters is effective with concurrent application of alkali
therapy. Most patients can be stone-free with minimal risk of
complications.
Clear localization with ultrasound during SWL is one of
the determinants of success. Ultrasound can localize radiolu-
cent uric acid stones of contrast material, ureteral stents and
catheters. The ultrasonographic image for stone disintegra-
tion during SWL treatment generally includes flattening of
the “bright mass” of renal stones and lengthening of the bright
mass along the dilated ureter. The fragmentation of lower
ureteral stones close to the orifice can be confirmed by a
phenomenon called the snowing sign, which occurs when the
fragments pass through the orifice into the bladder and fall
through the full bladder. However, these images will be ob-
tained only when the stones are located in an expansive cham-
ber where the fragments can disperse. It is not always easy to
judge the degree of stone fragmentation. For this reason, if the
stones seem to have been fragmented, about 10 minutes of
treatment will be routinely added to disintegrate the stones as
completely as possible.
Stone location has a notable impact on the results of SWL.
SWL with ultrasound-guided lithotripters is easy and efficient
for radiolucent uric acid stones smaller than 20 mm, owing to
the better direct localization of the stones. Table 2 shows that
better results were achieved for renal stones compared with
those reported in the literature.2,4,5 Although uric acid stones
in the ureter can also be treated with in situ SWL, the ultra-
sound localization of ureteral stones is often much more
difficult than that of renal stones. Thus, it is important that
once visualized by ultrasound, upper ureteral stones should be
disintegrated adequately in a single SWL session, if possible, in
order to avoid the difficulty of localizing the migrated residual
stone at a second session. In addition, because of the absence
of an expansive chamber around ureteral stones, the frag-
ments forming on the surface of the stones cannot scatter, so
a shell will form surrounding the stone. This shell may absorb
and reflect shock wave energy, thereby reducing disintegration
of the stone core.6 As a result, more energy and retreatment are
often required for ureteral stones than renal stones at a similar
burden to achieve a similar stone-free rate. In addition, to
improve the disintegration of ureteral stones as well as stones
in other locations such as the calyx, we routinely advise pa-
tients to take 400–500 mL water 30 minutes before the begin-
ning of SWL. The absorbed water can increase the fluid–stone
interface and flush away the fragments to expose the surface of
the remaining portion of the stone, thereby facilitating shock
Table 4. Stone composition from infrared spectroscopy and polarized microscopy
Stone composition EDAP LT-01 Dornier Compact S
Uric acid, % 91.10 88.00
Uric acid and whewellite, % 5.3 7.3
Uric acid and apatite, % 2.4 2.9
Sodium hydrogen urate and whewellite, % 1.2 1.8
Table 3. Complications
Complication EDAP LT-01 Dornier Compact S
Vagal reaction, % 13.0 15.1
Moderate haematuria, % 45.7 60.4
UTI with fever, % 10.9 07.5
Renal colic, % 30.4 17.0
UTI = urinary tract infection.
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wave delivery through the fresh fluid–stone interface to de-
stroy the remainder of the stone. According to our limited
experience, ultrasound localization of ureteral stones between
the L4 level and the lower border of the sacroiliac joint is
extremely difficult and even impossible, especially when there
is no marked proximal dilatation of the ureter.7 In this case,
stone manipulation is required before SWL.8–10 This auxiliary
procedure is more suitable for radiolucent ureteral stones that
cannot be localized by ultrasound during in situ SWL, and
facilitates stone localization as well as the creation of an
expansion chamber around the stone to ensure a better result
with SWL.
In our series, we also noticed the obvious correlation be-
tween the stone-free rate and time after SWL (Table 2). Accord-
ing to our experience, the ultrasound image of stones soon
after SWL can sometimes be misleading. Some stones that
appeared to be incompletely fragmented or even unchanged
on ultrasound images soon after SWL were absent 3 months
later, while a few stones that had initially been considered to
be completely fragmented were still observed 3 months later.
This phenomenon is similar to that of post-SWL fluoroscopy
for calculi stones.11,12 The reason may partly be related to the
resolution of ultrasonography. Therefore, we suggest that
a second SWL or auxiliary procedure is not generally neces-
sary within 2–3 months after the first SWL, particularly for
stones smaller than 20 mm, if there are no severe complica-
tions. Meanwhile, postoperative patients with larger uric acid
stones in the kidney that are not verified by ultrasound to have
been completely fragmented should not be encouraged to do
strong exercises, in case the large residual stones move into the
ureter.
The higher stone-free rate with SWL for uric acid stones in
our series may be related to the combination with alkali
therapy. It is well known that the alkalization of urine is an
effective method to prevent the formation of uric acid stones
and dissolve uric acid stones that have formed previously.13,14
Uric acid stones may be dissolved using intravenous alkali or
oral alkali combined with high fluid intake and allopurinol
treatment.15,16 However, it often takes several months to dis-
solve pure uric acid stones, and it is very difficult to dissolve
mixed stones of uric acid and calcium oxalate. Theoretically,
alkalization of urine may improve the stone-free rate of SWL
for uric acid stones in three ways: the surface area of the stone
may be greatly increased after disintegration of the primary
stone, thereby facilitating the dissolution of the residual stone;
the insoluble outer oxalate layers of some uric acid stones are
broken off by shock waves, so alkali therapy can dissolve the
uric acid cores of the stones; and the residual fragments fall-
ing into the ureter after SWL, which may not be localized by
ultrasound, may be dissolved by alkaline urine. Furthermore,
this mechanism shows that the complete clearance of stone
particles as a “stone embryo” is also essential for preventing
stone recurrence.
Our data show that SWL with the second generation of
ultrasound-guided lithotripters for uric acid stones in the
kidney or ureter is safe and effective. SWL combined with
alkali therapy may further improve the efficacy of treatment of
uric acid stones.
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